Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evexomostat - SynDevRx

Drug Profile

Evexomostat - SynDevRx

Alternative Names: MetAP2 inhibitor - SynDevRx; SDX-7320

Latest Information Update: 27 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SynDevRx, Inc
  • Developer Memorial Sloan-Kettering Cancer Center; SynDevRx, Inc
  • Class Antineoplastics; Cyclohexanes; Drug conjugates; Sesquiterpenes; Unsaturated fatty acids
  • Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Triple negative breast cancer
  • Phase I/II Breast cancer
  • Phase I Solid tumours
  • Preclinical Colorectal cancer; Interstitial lung diseases

Most Recent Events

  • 27 Jun 2023 3798119- No significant data, only methods of trial mentioned
  • 14 Apr 2023 Pharmacodynamics data from the preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 03 Oct 2022 Phase-II clinical trials in Triple-negative-breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT05570253)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top